Galera enrols last patient in Phase IIb trial of GC4419 to treat oral mucositis

US-based biotechnology company Galera Therapeutics has concluded enrolment in the Phase IIb clinical trial of GC4419 for the treatment of oral mucositis (OM) in patients with head and neck cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news